| EQIX |
Report |
Revenue (Q2 2026) |
IN-LINE |
pred ~$2,600M vs. cons $2,591M |
MEDIUM |
| EQIX |
Report |
AFFO per Share (Q2 2026) |
BEAT |
pred ~$11.55 vs. cons $11.36 |
MEDIUM |
| EQIX |
Report |
MRR Churn (Q2 2026) |
IN-LINE |
pred ~2.1% vs. cons ~2.21% |
MEDIUM |
| EQIX |
Guide |
Revenue Growth — FY 2026 (FY 2026) |
UNCHANGED |
guide ~10.5-11.5% vs. cons $10,245M |
MEDIUM |
| EQIX |
Guide |
AFFO/sh Growth — FY 2026 (FY 2026) |
BETTER |
guide ~9.5-11.5% (mid ~$43.40) vs. cons $43.14 |
MEDIUM |
| EQIX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+5.0% |
— |
MEDIUM |
| EQIX |
Return |
5-day cumulative residual |
+3.0% (FADE) |
FADE — implied out-period math (back-half ~0.7% below cons) pulls estimates down post-beat; partial give-back of day-1 pop |
MEDIUM |